You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 21, 2024

Details for Patent: 10,251,895


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,251,895 protect, and when does it expire?

Patent 10,251,895 protects DUOBRII and is included in one NDA.

This patent has twenty-eight patent family members in nineteen countries.

Summary for Patent: 10,251,895
Title:Topical compositions and methods for treating psoriasis
Abstract: Topical pharmaceutical compositions comprise a combination of a corticosteroid a retinoid; and methods for treating psoriasis with same.
Inventor(s): Dow; Gordon J. (Greenbrae, CA), Pillai; Radhakrishnan (Santa Rosa, CA), Bhatt; Varsha D. (San Francisco, CA)
Assignee: Valeant Pharmaceuticals North America (Bridgewater, NJ)
Application Number:15/173,961
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,251,895
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

United States Patent 10,251,895: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

The United States Patent 10,251,895, hereafter referred to as the '895 patent, is a critical component of the intellectual property portfolio of Bausch Health, particularly in the context of pharmaceutical products such as Duobrii® and Bryhali®. This patent, along with others, has been at the center of a significant patent infringement case involving Bausch Health and Padagis Israel Pharmaceuticals. Here, we delve into the scope, claims, and the broader patent landscape surrounding this patent.

Background of the Patent

The '895 patent is one of several patents owned by Bausch Health that protect their pharmaceutical products. Specifically, it is associated with the formulation and composition of topical treatments involving halobetasol propionate and tazarotene, key ingredients in Duobrii® and Bryhali®[4].

Claims of the '895 Patent

The '895 patent includes several claims that define the scope of the invention. Here are some key claims:

  • Claim 3 and 6: These claims are central to the patent and describe specific formulations of halobetasol propionate and tazarotene, including their concentrations and the solvents used. These claims are asserted against Padagis's proposed generic versions of the products[4].

Scope of the Patent

The scope of the '895 patent is defined by its claims, which outline the specific compositions and methods of preparation for the topical treatments. Here are some key aspects:

  • Formulation: The patent describes a formulation that combines halobetasol propionate and tazarotene in specific concentrations. This combination is designed to treat skin conditions such as psoriasis and acne[4].
  • Solvents and Compatibility: The patent details the solvents used and the compatibility studies conducted to ensure the stability and efficacy of the formulation[4].

Patent Landscape

The '895 patent operates within a complex patent landscape that includes other related patents owned by Bausch Health.

  • Related Patents: Other patents such as U.S. Patent Nos. 10,426,787 ('787 patent), 8,809,307 ('307 patent), and 10,478,502 ('502 patent) are also part of this landscape. These patents collectively protect various aspects of the pharmaceutical products, including their formulations, methods of preparation, and uses[4].
  • Global Dossier: The Global Dossier service provided by the USPTO allows users to access the file histories of related applications from participating IP Offices, which can be crucial for understanding the broader patent family and any international filings related to the '895 patent[1].

Patent Infringement and Validity

The '895 patent has been at the center of a patent infringement case against Padagis Israel Pharmaceuticals.

  • Infringement Claims: Bausch Health has asserted that Padagis's proposed generic versions of Duobrii® and Bryhali® infringe on the claims of the '895 patent, among others. The parties have stipulated to infringement, but the validity of the claims has been contested[4].
  • Validity Challenges: Padagis has argued that the claims of the '895 patent are invalid due to obviousness under 35 U.S.C. § 103 and indefiniteness under 35 U.S.C. § 112. However, the court has found that Padagis failed to prove these claims invalid[4].

Claim Construction and Obviousness Analysis

The court's analysis of the claims involved a detailed construction of the claim language and an assessment of whether the claims were obvious.

  • Claim Construction: The court's construction of the claims was critical in determining the scope of the invention and whether Padagis's products infringed on these claims. The court rejected Padagis's argument that statistical significance was required to satisfy the synergy limitations of the '895 and '787 patents[2][4].
  • Obviousness: The obviousness analysis required determining whether a person of ordinary skill in the art (POSA) would have found the combination of halobetasol propionate and tazarotene obvious. The court found that Padagis did not provide sufficient evidence to prove obviousness[4].

Development and Testing

The development of the formulation protected by the '895 patent involved extensive research and testing.

  • Solubility and Compatibility Studies: The development process included solubility and compatibility studies to identify suitable solvents and ensure the stability of the formulation[4].
  • Clinical Studies: The formulation underwent various clinical studies, including Phase 1, 2, and 3 trials, as well as a long-term safety study. The results of these studies, particularly the "201 Study," showed a significant level of effectiveness for the formulation[4].

Impact on Pharmaceutical Industry

The '895 patent and related patents have significant implications for the pharmaceutical industry.

  • Innovation and Competition: The protection afforded by these patents can influence innovation and competition in the market. Generic manufacturers like Padagis must navigate these patents to bring their products to market[4].
  • Regulatory Environment: The patents also interact with regulatory requirements, such as those set by the FDA. Compliance with these regulations is crucial for the approval and marketing of pharmaceutical products[5].

Conclusion

The United States Patent 10,251,895 is a pivotal patent in the pharmaceutical industry, particularly in the context of topical treatments involving halobetasol propionate and tazarotene. Understanding its scope, claims, and the broader patent landscape is essential for navigating the complex world of pharmaceutical intellectual property.

Key Takeaways

  • Scope and Claims: The '895 patent defines specific formulations and methods of preparation for topical treatments.
  • Patent Landscape: It operates within a complex landscape that includes other related patents.
  • Infringement and Validity: The patent has been at the center of a significant infringement case, with challenges to its validity.
  • Development and Testing: Extensive research and clinical studies were conducted to develop and validate the formulation.
  • Industry Impact: The patent has significant implications for innovation, competition, and regulatory compliance in the pharmaceutical industry.

FAQs

Q1: What is the main subject of the '895 patent? The '895 patent primarily covers specific formulations and compositions of topical treatments involving halobetasol propionate and tazarotene.

Q2: Which company owns the '895 patent? The '895 patent is owned by Bausch Health.

Q3: What is the significance of the "201 Study" mentioned in the context of the '895 patent? The "201 Study" was a clinical study required by the FDA that showed a surprising level of effectiveness for the formulation protected by the '895 patent.

Q4: How does the '895 patent interact with other patents in the same family? The '895 patent is part of a broader patent family that includes other patents such as the '787, '307, and '502 patents, all of which protect various aspects of the pharmaceutical products.

Q5: What was the outcome of the patent infringement case involving the '895 patent? The court found that Padagis failed to prove that the claims of the '895 patent were invalid, and thus the patent remains valid.

Sources

  1. USPTO - Search for patents.
  2. NOT FOR PUBLICATION UNITED STATES DISTRICT COURT.
  3. Patent Claims and Patent Scope - Search eLibrary :: SSRN.
  4. Bausch Health Ir. v. Padagis Isr. Pharm., Civil Action 20-5426 (SRC).
  5. SOL-GEL TECHNOLOGIES LTD..

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,251,895

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bausch DUOBRII halobetasol propionate; tazarotene LOTION;TOPICAL 209354-001 Apr 25, 2019 RX Yes Yes 10,251,895 ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.